Viking Fund Management LLC Has $2.74 Million Holdings in Pfizer Inc. (NYSE:PFE)

Share on StockTwits

Viking Fund Management LLC increased its position in Pfizer Inc. (NYSE:PFE) by 34.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 70,000 shares of the biopharmaceutical company’s stock after acquiring an additional 18,000 shares during the quarter. Viking Fund Management LLC’s holdings in Pfizer were worth $2,743,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. 1 North Wealth Services LLC acquired a new stake in Pfizer during the third quarter worth about $29,000. Bourgeon Capital Management LLC bought a new position in Pfizer during the third quarter valued at about $32,000. Salomon & Ludwin LLC raised its holdings in Pfizer by 362.7% in the 3rd quarter. Salomon & Ludwin LLC now owns 893 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 700 shares in the last quarter. B & T Capital Management DBA Alpha Capital Management acquired a new position in Pfizer in the 3rd quarter valued at approximately $36,000. Finally, Sageworth Trust Co acquired a new position in Pfizer in the 3rd quarter valued at approximately $44,000. 70.21% of the stock is owned by hedge funds and other institutional investors.

PFE stock opened at $40.67 on Thursday. Pfizer Inc. has a 1-year low of $33.97 and a 1-year high of $44.56. The firm has a market cap of $221.75 billion, a P/E ratio of 13.56, a P/E/G ratio of 4.24 and a beta of 0.65. The business’s 50 day moving average is $38.90 and its 200-day moving average is $38.18. The company has a current ratio of 0.90, a quick ratio of 0.68 and a debt-to-equity ratio of 0.55.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.13. The business had revenue of $12.68 billion during the quarter, compared to the consensus estimate of $12.37 billion. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. Pfizer’s revenue was down 4.6% on a year-over-year basis. During the same quarter last year, the company earned $0.78 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.97 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 31st will be paid a $0.38 dividend. This represents a $1.52 annualized dividend and a dividend yield of 3.74%. The ex-dividend date is Thursday, January 30th. This is an increase from Pfizer’s previous quarterly dividend of $0.36. Pfizer’s payout ratio is currently 48.00%.

Several analysts have recently weighed in on the company. Bank of America initiated coverage on Pfizer in a report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price objective on the stock. Credit Suisse Group restated a “hold” rating and issued a $41.30 target price on shares of Pfizer in a research note on Wednesday, November 6th. ValuEngine upgraded Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Royal Bank of Canada initiated coverage on Pfizer in a research report on Monday, January 6th. They issued an “outperform” rating and a $46.00 target price for the company. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Pfizer in a research note on Tuesday, October 29th. Nine investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Pfizer has a consensus rating of “Hold” and a consensus price target of $43.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Closed-End Mutual Funds

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.